The origins of the company go back as far as 1912, when János Köves established Phylaxia Vaccine Production Co. His aim was to develop and produce a serum to protect the numerous swine population of the region against a severe outbreak of swine fever. This was the beginning of a tradition of prominent research, bringing solutions to livestock producers to help them in their fight against major diseases.

Famous Hungarian scientists such as József Marek, Aladár Aujeszky, Domokos Derzsy and Adorján Bartha, names that are familiar to veterinarians worldwide, have been closely associated with the development of the company.

Ever since, the company’s work has been closely and intimately tied up with biological research and development.

At the time of the fall of the socialist regime in 1991, Phylaxia also responded to changes: with two partners it established our company to enter the international market. Since 1999 Ceva-Phylaxia’s sole shareholder has been Ceva Santé Animale. The presence of Ceva-Phylaxia Campus is continuously increasing in the Hungarian market, the company is reaping success in the escalating international competition, also in major meat producing markets like Brazil, Thailand, China, Mexico and South Africa. 90% of the company turnover comes from exports.

The multinational brought into the wedding package its own vaccines (Coglapest, Coglavax, Cevac IBD L, etc.) and research facilities in the USA, where further famous researchers, like Rollie Winterfield, Steve Hitchner and Al Cosgrove (who first identified the Gumboro disease) were associated with the American branch of the company.
 The Campus researchers are internationally renowned experts. It is important to remain open to new and innovative solutions that help the company maintain its market leading position in Hungary. Our key strength is the expertise company experts and specialists have amassed during the past decades, particularly with respect to the achievements of the targeted researches concerning certain diseases. The company has lately provided significant resources for such focused research that ultimately enabled and promoted the development of leading vaccines prevailing in the market. Registration is another key area of our activities. As a result of this important activity the company has more than 2300 marketing licences globally.